[HTML][HTML] Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIB
CD Heldermon, KK Ohlemiller, ED Herzog, C Vogler… - Molecular Therapy, 2010 - cell.com
Sanfilippo syndrome type B (MPS IIIB) is a lysosomal storage disease resulting from a
deficiency of N-acetyl-glucosaminidase (NAGLU) activity. In an attempt to correct the …
deficiency of N-acetyl-glucosaminidase (NAGLU) activity. In an attempt to correct the …
[PDF][PDF] Therapeutic Efficacy of Bone Marrow Transplant, Intracranial AAV-mediated Gene Therapy, or Both in the Mouse Model of MPS IIIB
CD Heldermon, KK Ohlemiller… - Molecular …, 2010 - orrocklab.zoology.wisc.edu
Mucopolysaccharidosis IIIB is a lysosomal storage disease resulting from a deficiency in N-
acetyl-glucosaminidase activity. Typically, the disease manifests clinically around 5 years of …
acetyl-glucosaminidase activity. Typically, the disease manifests clinically around 5 years of …
Therapeutic Efficacy of Bone Marrow Transplant, Intracranial AAV-mediated Gene Therapy, or Both in the Mouse Model of MPS IIIB.
CD Heldermon, KK Ohlemiller, ED Herzog… - Molecular …, 2010 - search.ebscohost.com
Sanfilippo syndrome type B (MPS IIIB) is a lysosomal storage disease resulting from a
deficiency of N-acetyl-glucosaminidase (NAGLU) activity. In an attempt to correct the …
deficiency of N-acetyl-glucosaminidase (NAGLU) activity. In an attempt to correct the …
[引用][C] Therapeutic Efficacy of Bone Marrow Transplant, Intracranial AAV-mediated Gene Therapy, or Both in the Mouse Model of MPS IIIB
CD Heldermon, KK Ohlemiller, ED Herzog, C Vogler… - Molecular …, 2010 - cir.nii.ac.jp
Therapeutic Efficacy of Bone Marrow Transplant, Intracranial AAV-mediated Gene Therapy,
or Both in the Mouse Model of MPS IIIB | CiNii Research CiNii 国立情報学研究所 学術情報 …
or Both in the Mouse Model of MPS IIIB | CiNii Research CiNii 国立情報学研究所 学術情報 …
[PDF][PDF] Therapeutic Efficacy of Bone Marrow Transplant, Intracranial AAV-mediated Gene Therapy, or Both in the Mouse Model of MPS IIIB
CD Heldermon, KK Ohlemiller, ED Herzog… - Molecular …, 2010 - academia.edu
Mucopolysaccharidosis IIIB is a lysosomal storage disease resulting from a deficiency in N-
acetyl-glucosaminidase activity. Typically, the disease manifests clinically around 5 years of …
acetyl-glucosaminidase activity. Typically, the disease manifests clinically around 5 years of …
Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIB.
CD Heldermon, KK Ohlemiller, ED Herzog… - … Therapy: the Journal …, 2010 - europepmc.org
Sanfilippo syndrome type B (MPS IIIB) is a lysosomal storage disease resulting from a
deficiency of N-acetyl-glucosaminidase (NAGLU) activity. In an attempt to correct the …
deficiency of N-acetyl-glucosaminidase (NAGLU) activity. In an attempt to correct the …
[HTML][HTML] Therapeutic Efficacy of Bone Marrow Transplant, Intracranial AAV-mediated Gene Therapy, or Both in the Mouse Model of MPS IIIB
CD Heldermon, KK Ohlemiller, ED Herzog, C Vogler… - Molecular Therapy, 2010 - Elsevier
Sanfilippo syndrome type B (MPS IIIB) is a lysosomal storage disease resulting from a
deficiency of N-acetyl-glucosaminidase (NAGLU) activity. In an attempt to correct the …
deficiency of N-acetyl-glucosaminidase (NAGLU) activity. In an attempt to correct the …
Therapeutic Efficacy of Bone Marrow Transplant, Intracranial AAV-mediated Gene Therapy, or Both in the Mouse Model of MPS IIIB
CD Heldermon, KK Ohlemiller, ED Herzog… - Molecular …, 2010 - profiles.wustl.edu
Sanfilippo syndrome type B (MPS IIIB) is a lysosomal storage disease resulting from a
deficiency of N-acetyl-glucosaminidase (NAGLU) activity. In an attempt to correct the …
deficiency of N-acetyl-glucosaminidase (NAGLU) activity. In an attempt to correct the …
[PDF][PDF] Therapeutic Efficacy of Bone Marrow Transplant, Intracranial AAV-mediated Gene Therapy, or Both in the Mouse Model of MPS IIIB
CD Heldermon, KK Ohlemiller, ED Herzog… - Molecular …, 2010 - researchgate.net
Mucopolysaccharidosis IIIB is a lysosomal storage disease resulting from a deficiency in N-
acetyl-glucosaminidase activity. Typically, the disease manifests clinically around 5 years of …
acetyl-glucosaminidase activity. Typically, the disease manifests clinically around 5 years of …
[HTML][HTML] Therapeutic Efficacy of Bone Marrow Transplant, Intracranial AAV-mediated Gene Therapy, or Both in the Mouse Model of MPS IIIB
CD Heldermon, KK Ohlemiller, ED Herzog… - Molecular …, 2010 - ncbi.nlm.nih.gov
Sanfilippo syndrome type B (MPS IIIB) is a lysosomal storage disease resulting from a
deficiency of N-acetyl-glucosaminidase (NAGLU) activity. In an attempt to correct the …
deficiency of N-acetyl-glucosaminidase (NAGLU) activity. In an attempt to correct the …